Literature DB >> 25113924

Prevalence of schizophrenia disability and associated mortality among Chinese men and women.

Tianli Liu1, Xinming Song1, Gong Chen1, Angela D Paradis2, Xiaoying Zheng3.   

Abstract

Schizophrenia is a major cause of psychiatric disability in China. In the present study, we estimated total and age-specific prevalence of both schizophrenia disability and associated mortality among Chinese women and men. We further examined whether sex differences in prevalence were attributable to mortality differences between men and women. Data from the Second China National Sample Survey on Disability (2006) and the 2007-2010 follow-up studies were utilized. Possibly psychiatrically disabled individuals were administered the World Health Organization Disability Assessment Schedule, Version II and the ICD-10 Symptom Checklist for Mental Disorders by trained clinical psychiatrists. In total, 0.37% of men and 0.44% of women were living with schizophrenia disability in China. We did not find statistically significant differences in the 4-year cumulative mortality between men and women. Overall standardized mortality ratios for the age groups of 18-29, 30-39, 40-49, 50-59, 60-69, and 70+ years were 120.89, 29.56, 15.06, 9.16, 10.57, and 4.95, respectively. In conclusion, mortality differences between men and women were unlikely to be a major contributor to sex differences in prevalence. Premature death among younger individuals experiencing schizophrenia disability warrants urgent attention.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Age; Disability; Mortality; Premature death; Prevalence; Schizophrenia; Sex

Mesh:

Year:  2014        PMID: 25113924     DOI: 10.1016/j.psychres.2014.04.042

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Assessment of functioning and disability in patients with schizophrenia using the WHO Disability Assessment Schedule 2.0 in a large-scale database.

Authors:  Ruey Chen; Tsan-Hon Liou; Kwang-Hwa Chang; Chia-Feng Yen; Hua-Fang Liao; Wen-Chou Chi; Kuei-Ru Chou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-11       Impact factor: 5.270

2.  Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.

Authors:  Jingping Zhao; Lehua Li; Jianguo Shi; Yi Li; Xiufeng Xu; Keqing Li; Lili Zhang; Shangli Cai; Yu Feng; Jianmin Zhuo; Weihong Liu; Huafei Lu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-02       Impact factor: 2.570

3.  The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.

Authors:  Ying Liang; Xin Yu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-21       Impact factor: 2.570

4.  Environmental Barriers and Functional Outcomes in Patients with Schizophrenia in Taiwan: The Capacity-Performance Discrepancy.

Authors:  Wei-Chih Lien; Wei-Ming Wang; Hui-Min David Wang; Feng-Huei Lin; Fen-Zhi Yao
Journal:  Int J Environ Res Public Health       Date:  2021-12-28       Impact factor: 3.390

5.  Socioeconomic inequality in rehabilitation service utilization for schizophrenia in China: Findings from a 7-year nationwide longitudinal study.

Authors:  Ruoxi Ding; Ping He; Xiaoying Zheng
Journal:  Front Psychiatry       Date:  2022-08-26       Impact factor: 5.435

6.  Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.

Authors:  Jia Liu; Lidan Cao; Jing Wu
Journal:  Front Public Health       Date:  2022-09-15

7.  Association of Urbanicity with Schizophrenia and Related Mortality in China: Association de l'urbanicité avec la schizophrénie et la mortalité qui y est reliée en Chine.

Authors:  Yanan Luo; Lihua Pang; Chao Guo; Lei Zhang; Xiaoying Zheng
Journal:  Can J Psychiatry       Date:  2020-09-03       Impact factor: 4.356

8.  The magnitude of disability in patients with schizophrenia in North West Ethiopia: A multicenter hospital-based cross-sectional study.

Authors:  Getnet Mihretie Beyene; Getasew Legas; Telake Azale; Mebrat Abera; Sintayehu Asnakew
Journal:  Heliyon       Date:  2021-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.